Suryaprakash Sambhara

List of Publications by Year
in descending order

Version: 2024-02-01

120 papers	7,148 citations	66234 42 h-index	62479 80 g-index
124 all docs	124 docs citations	124 times ranked	9727 citing authors

#	Article	IF	Citations
1	Heterogeneous Ribonucleoprotein A1 (hnRNPA1) Interacts with the Nucleoprotein of the Influenza a Virus and Impedes Virus Replication. Viruses, 2022, 14, 199.	1.5	4
2	Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults. Influenza and Other Respiratory Viruses, 2022, 16, 562-567.	1.5	6
3	Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults. Npj Vaccines, 2021, 6, 25.	2.9	23
4	Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science, 2021, 372, 1108-1112.	6.0	210
5	A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	15
6	Influenza Virus Infects and Depletes Activated Adaptive Immune Responders. Advanced Science, 2021, 8, e2100693.	5.6	7
7	Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18â€“64 Years: A Randomized Open-Label Trial. Clinical Infectious Diseases, 2021, 73, 1973-1981.	2.9	18
8	Quinazolin-derived myeloperoxidase inhibitor suppresses influenza A virus-induced reactive oxygen species, pro-inflammatory mediators and improves cell survival. PLoS ONE, 2021, 16, e0254632.	1.1	1
9	Innate lymphoid cells (ILC) in SARS-CoV-2 infection. Molecular Aspects of Medicine, 2021, 80, 101008.	2.7	10
10	Adenoviral vectorâ€based platforms for developing effective vaccines to combat respiratory viral infections. Clinical and Translational Immunology, 2021, 10, e1345.	1.7	14
11	Human innate lymphoid cells in influenza infection and vaccination. Critical Reviews in Immunology, 2021, 41, 57-82.	1.0	1
12	Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial. Clinical Infectious Diseases, 2020, 71, 1704-1714.	2.9	67
13	Influenza A Virus Nucleoprotein Activates the JNK Stress-Signaling Pathway for Viral Replication by Sequestering Host Filamin A Protein. Frontiers in Microbiology, 2020, 11, 581867.	1.5	8
14	Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines. Vaccines, 2020, 8, 574.	2.1	40
15	SARSâ€CoVâ€2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination. Advanced Materials, 2020, 32, e2005637.	11.1	74
16	Vaccines: SARSâ€CoVâ€2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination (Adv.) Tj ETQq0 0 0 rgBT /Overloc	11.1	1
17	A Dual-Functioning 5Ê¹-PPP-NS1shRNA that Activates a RIG-I Antiviral Pathway and Suppresses Influenza NS1. Molecular Therapy - Nucleic Acids, 2020, 19, 1413-1422.	2.3	3
18	Conserved Oligomeric Golgi (COG) Complex Proteins Facilitate Orthopoxvirus Entry, Fusion and Spread. Viruses, 2020, 12, 707.	1.5	16

#	Article	IF	Citations
19	Influenza virus NS1- C/EBPÎ² gene regulatory complex inhibits RIG-I transcription. Antiviral Research, 2020, 176, 104747.	1.9	7
20	Discovery of Retro-1 Analogs Exhibiting Enhanced Anti-vaccinia Virus Activity. Frontiers in Microbiology, 2020, 11, 603.	1.5	11
21	Prospective cohort study of influenza vaccine effectiveness among healthcare personnel in Lima, Peru: Estudio Vacuna de Influenza Peru, 2016â€2018. Influenza and Other Respiratory Viruses, 2020, 14, 391-402.	1.5	7
22	Kinetics of antibody response to influenza vaccination in renal transplant recipients. Transplant Immunology, 2019, 53, 51-60.	0.6	20
23	Standard-Dose Intradermal Influenza Vaccine Elicits Cellular Immune Responses Similar to Those of Intramuscular Vaccine in Men With and Those Without HIV Infection. Journal of Infectious Diseases, 2019, 220, 743-751.	1.9	6
24	Nasal delivery of H5N1 avian influenza vaccine formulated with GenJetâ„¢ or in vivo-jetPEI^{Â®}induces enhanced serological, cellular and protective immune responses. Drug Delivery, 2018, 25, 773-779.	2.5	10
25	An ELISA-based method for detection of rabies virus nucleoprotein-specific antibodies in human antemortem samples. PLoS ONE, 2018, 13, e0207009.	1.1	20
26	Longevity of adenovirus vector immunity in mice and its implications for vaccine efficacy. Vaccine, 2018, 36, 6744-6751.	1.7	15
27	A Bovine Adenoviral Vector-Based H5N1 Influenza -Vaccine Provides Enhanced Immunogenicity and Protection at a Significantly Low Dose. Molecular Therapy - Methods and Clinical Development, 2018, 10, 210-222.	1.8	14
28	Inactivated Influenza Vaccines. , 2018, , 456-488.e21.		14
29	Influenza virus exploits tunneling nanotubes for cell-to-cell spread. Scientific Reports, 2017, 7, 40360.	1.6	110
30	Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice. Vaccine, 2017, 35, 3318-3325.	1.7	8
31	Monkeypox Virus Host Factor Screen Using Haploid Cells Identifies Essential Role of GARP Complex in Extracellular Virus Formation. Journal of Virology, 2017, 91, .	1.5	54
32	Vaccine approaches conferring cross-protection against influenza viruses. Expert Review of Vaccines, 2017, 16, 1141-1154.	2.0	41
33	An Adjuvanted A(H5N1) Subvirion Vaccine Elicits Virus-Specific Antibody Response and Improves Protection Against Lethal Influenza Viral Challenge in Mouse Model of Protein Energy Malnutrition. Journal of Infectious Diseases, 2017, 216, S560-S565.	1.9	2
34	Critical role of RIG-I and MDA5 in early and late stages of Tulane virus infection. Journal of General Virology, 2017, 98, 1016-1026.	1.3	11
35	Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses. PLoS ONE, 2017, 12, e0186244.	1.1	15
36	Human Heat shock protein 40 (Hsp40/DnaJB1) promotes influenza A virus replication by assisting nuclear import of viral ribonucleoproteins. Scientific Reports, 2016, 6, 19063.	1.6	48

#	Article	IF	Citations
37	An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1909-1917.	1.7	12
38	RIG-I ligand enhances the immunogenicity of recombinant H7HA protein. Cellular Immunology, 2016, 304-305, 55-58.	1.4	6
39	Seasonal Influenza Vaccination of Children Induces Humoral and Cell-Mediated Immunity Beyond the Current Season: Cross-reactivity With Past and Future Strains. Journal of Infectious Diseases, 2016, 214, 1477-1486.	1.9	15
40	High-dose influenza vaccine favors acute plasmablast responses rather than long-term cellular responses. Vaccine, 2016, 34, 4594-4601.	1.7	19
41	Cell-Mediated Immunity Against Antigenically Drifted Influenza A(H3N2) Viruses in Children During a Vaccine Mismatch Season. Journal of Infectious Diseases, 2016, 214, 1030-1038.	1.9	8
42	Non-neutralizing antibodies induced by seasonal influenza vaccine prevent, not exacerbate A(H1N1)pdm09 disease. Scientific Reports, 2016, 6, 37341.	1.6	22
43	Rapamycin Does Not Impede Survival or Induction of Antibody Responses to Primary and Heterosubtypic Influenza Infections in Mice. Viral Immunology, 2016, 29, 487-493.	0.6	4
44	Prior infection with influenza virus but not vaccination leaves a long-term immunological imprint that intensifies the protective efficacy of antigenically drifted vaccine strains. Vaccine, 2016, 34, 495-502.	1.7	31
45	A highly immunogenic vaccine against A/H7N9 influenza virus. Vaccine, 2016, 34, 744-749.	1.7	12
46	NADPH Oxidase 1 Is Associated with Altered Host Survival and T Cell Phenotypes after Influenza A Virus Infection in Mice. PLoS ONE, 2016, 11, e0149864.	1.1	17
47	Age, serum 25-hydroxyvitamin D and vitamin D receptor (VDR) expression and function in peripheral blood mononuclear cells. Oncotarget, 2016, 7, 35512-35521.	0.8	12
48	Increased Dietary Salt Intake Does Not Influence Influenza A Virusâ€“Induced Disease Severity in Mice. Viral Immunology, 2015, 28, 532-537.	0.6	1
49	A Newly Emerged Swine-Origin Influenza A(H3N2) Variant Dampens Host Antiviral Immunity but Induces Potent Inflammasome Activation. Journal of Infectious Diseases, 2015, 212, 1923-1929.	1.9	5
50	Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses. Open Forum Infectious Diseases, 2015, 2, ofv052.	0.4	37
51	NLRC5 interacts with RIGâ€I to induce a robust antiviral response against influenza virus infection. European Journal of Immunology, 2015, 45, 758-772.	1.6	49
52	Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50â€“80 years of age. Human Vaccines and Immunotherapeutics, 2014, 10, 1195-1203.	1.4	17
53	Influenza A viral nucleoprotein interacts with cytoskeleton scaffolding protein Î±â€actininâ€4 for viral replication. FEBS Journal, 2014, 281, 2899-2914.	2.2	38
54	Activation of the RIG-I Pathway during Influenza Vaccination Enhances the Germinal Center Reaction, Promotes T Follicular Helper Cell Induction, and Provides a Dose-Sparing Effect and Protective Immunity. Journal of Virology, 2014, 88, 13990-14001.	1.5	70

#	Article	IF	Citations
55	Adenoviral vector expressing murine Î²-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice. Virus Research, 2013, 177, 55-61.	1.1	8
56	Nox1 as a Therapeutic Target to Improve Survival in Influenza a Infection. Free Radical Biology and Medicine, 2013, 65, S125-S126.	1.3	0
57	RIG-I Goes Beyond Naked Recognition. Cell Host and Microbe, 2013, 13, 247-249.	5.1	6
58	Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time. Virus Research, 2013, 178, 398-403.	1.1	24
59	Cytokine and Chemokine Profiles in Lung Tissues from Fatal Cases of 2009 Pandemic Influenza A (H1N1). American Journal of Pathology, 2013, 183, 1258-1268.	1.9	119
60	Protein Energy Malnutrition Decreases Immunity and Increases Susceptibility to Influenza Infection in Mice. Journal of Infectious Diseases, 2013, 207, 501-510.	1.9	103
61	Influenza A virus nucleoprotein induces apoptosis in human airway epithelial cells: implications of a novel interaction between nucleoprotein and host protein Clusterin. Cell Death and Disease, 2013, 4, e562-e562.	2.7	78
62	Broadly Protective Adenovirus-Based Multivalent Vaccines against Highly Pathogenic Avian Influenza Viruses for Pandemic Preparedness. PLoS ONE, 2013, 8, e62496.	1.1	41
63	Age and Vitamin D Receptor (VDR) Expression and Functionality in Peripheral Blood Mononuclear Cells (PBMC). FASEB Journal, 2013, 27, lb252.	0.2	0
64	TLR7 Recognition Is Dispensable for Influenza Virus A Infection but Important for the Induction of Hemagglutinin-Specific Antibodies in Response to the 2009 Pandemic Split Vaccine in Mice. Journal of Virology, 2012, 86, 10988-10998.	1.5	58
65	Influenza A Virus Neuraminidase Protein Enhances Cell Survival through Interaction with Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) Protein. Journal of Biological Chemistry, 2012, 287, 15109-15117.	1.6	29
66	Improving influenza vaccines. Expert Review of Vaccines, 2012, 11, 871-872.	2.0	6
67	Rapid Differentiation of Monocytes into Type I IFN-Producing Myeloid Dendritic Cells as an Antiviral Strategy against Influenza Virus Infection. Journal of Immunology, 2012, 189, 2257-2265.	0.4	52
68	Impact of Preexisting Adenovirus Vector Immunity on Immunogenicity and Protection Conferred with an Adenovirus-Based H5N1 Influenza Vaccine. PLoS ONE, 2012, 7, e33428.	1.1	65
69	Strategies to alleviate original antigenic sin responses to influenza viruses. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13751-13756.	3.3	81
70	The 3â€² Untranslated Regions of Influenza Genomic Sequences Are 5â€²PPP-Independent Ligands for RIG-I. PLoS ONE, 2012, 7, e32661.	1.1	39
71	Critical Role of an Antiviral Stress Granule Containing RIG-I and PKR in Viral Detection and Innate Immunity. PLoS ONE, 2012, 7, e43031.	1.1	294
72	Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population. , 2012, 3, 68-90.		58

#	Article	IF	Citations
73	17Î²-Estradiol restores antibody responses to an influenza vaccine in a postmenopausal mouse model. Vaccine, 2011, 29, 2515-2518.	1.7	46
74	Influenza A Virus Nucleoprotein Exploits Hsp40 to Inhibit PKR Activation. PLoS ONE, 2011, 6, e20215.	1.1	64
75	Increased MDSC Accumulation and Th2 Biased Response to Influenza A Virus Infection in the Absence of TLR7 in Mice. PLoS ONE, 2011, 6, e25242.	1.1	65
76	PAMPer and tRIGer: ligand-induced activation of RIG-I. Trends in Biochemical Sciences, 2011, 36, 314-319.	3.7	8
77	NLRX1 Protein Attenuates Inflammatory Responses to Infection by Interfering with the RIG-I-MAVS and TRAF6-NF-Î²B Signaling Pathways. Immunity, 2011, 34, 854-865.	6.6	323
78	Infection of Lung Epithelial Cells with Pandemic 2009 A(H1N1) Influenza Viruses Reveals Isolate-Specific Differences in Infectivity and Host Cellular Responses. Viral Immunology, 2011, 24, 89-99.	0.6	7
79	Improving immunogenicity and effectiveness of influenza vaccine in older adults. Expert Review of Vaccines, 2011, 10, 1529-1537.	2.0	27
80	Patients Hospitalized with pH1N1 Influenza in an Academic Community Medical Center. Open Respiratory Medicine Journal, 2011, 5, 19-23.	1.3	7
81	Significant Impact of Sequence Variations in the Nucleoprotein on CD8 T Cell-Mediated Cross-Protection against Influenza A Virus Infections. PLoS ONE, 2010, 5, e10583.	1.1	25
82	Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10172-10177.	3.3	98
83	Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccin, 2010, 6, 178-188.	2.4	52
84	5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication. Virology Journal, 2010, 7, 102.	1.4	27
85	H5N1 Avian Influenza: Preventive and Therapeutic Strategies Against a Pandemic. Annual Review of Medicine, 2010, 61, 187-198.	5.0	38
86	Moving influenza vaccines forward. Expert Review of Vaccines, 2009, 8, 375-377.	2.0	8
87	Early Control of H5N1 Influenza Virus Replication by the Type I Interferon Response in Mice. Journal of Virology, 2009, 83, 5825-5834.	1.5	93
88	RIG-I activation inhibits ebolavirus replication. Virology, 2009, 392, 11-15.	1.1	42
89	Antiviral defense: RIG-Ing the immune system to STING. Cytokine and Growth Factor Reviews, 2009, 20, 1-5.	3.2	13
90	Cytoplasmic nucleic acid sensors in antiviral immunity. Trends in Molecular Medicine, 2009, 15, 359-368.	3.5	59

#	Article	IF	Citations
91	Immunosenescence and Influenza Vaccine Efficacy. Current Topics in Microbiology and Immunology, 2009, 333, 413-429.	0.7	83
92	Vaccines against epidemic and pandemic influenza. Expert Opinion on Drug Delivery, 2008, 5, 1139-1157.	2.4	29
93	Vaccines against Influenza A (H5N1): Evidence of Progress. Journal of Infectious Diseases, 2008, 198, 629-631.	1.9	14
94	A Broadly Protective Vaccine against Globally Dispersed Clade 1 and Clade 2 H5N1 Influenza Viruses. Journal of Infectious Diseases, 2008, 197, 1185-1188.	1.9	58
95	NS1 Protein of Influenza A Virus Inhibits the Function of Intracytoplasmic Pathogen Sensor, RIG-I. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 263-269.	1.4	258
96	Needle-Free Skin Patch Delivery of a Vaccine for a Potentially Pandemic Influenza Virus Provides Protection against Lethal Challenge in Mice. Vaccine Journal, 2007, 14, 926-928.	3.2	39
97	Breaking the immunogenicity barrier of bird flu vaccines. Lancet, The, 2007, 370, 544-545.	6.3	8
98	Role of Host Cytokine Responses in the Pathogenesis of Avian H5N1 Influenza Viruses in Mice. Journal of Virology, 2007, 81, 2736-2744.	1.5	369
99	H5N1 vaccine hits the target, but not the bull's eye. Lancet Infectious Diseases, The, 2007, 7, 503-505.	4.6	5
100	The innate immune system: a repository for future drugs?. Expert Review of Anti-Infective Therapy, 2007, 5, 1-5.	2.0	13
101	Challenges for vaccination in the elderly. Immunity and Ageing, 2007, 4, 9.	1.8	173
102	New Pre-pandemic Influenza Vaccines: An Egg- and Adjuvant-independent Human Adenoviral Vector Strategy Induces Long-lasting Protective Immune Responses in Mice. Clinical Pharmacology and Therapeutics, 2007, 82, 665-671.	2.3	40
103	Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet, The, 2006, 367, 475-481.	6.3	179
104	Avian influenza vaccines: what's all the flap?. Lancet, The, 2006, 367, 1636-1638.	6.3	20
105	A Distal Regulatory Region Is Required for Constitutive and IFN-Î²-Induced Expression of MurineTLR9Gene. Journal of Immunology, 2005, 175, 7407-7418.	0.4	29
106	Innate immunity in aging: impact on macrophage function. Aging Cell, 2004, 3, 161-167.	3.0	380
107	Impaired antigen-induced CD8+ T cell clonal expansion in aging is due to defects in antigen presenting cell function. Cellular Immunology, 2004, 229, 86-92.	1.4	81
108	Immunity to Influenza: The Challenges of Protecting an Aging Population. Immunologic Research, 2004, 29, 113-124.	1.3	77

#	Article	IF	Citations
109	Cytotoxic T Lymphocyte Reactivity to gp100, MelanA/MART-1, and Tyrosinase, in HLA-A2-Positive Vitiligo Patients. Journal of Investigative Dermatology, 2003, 121, 550-556.	0.3	90
110	Cutting Edge: Impaired Toll-Like Receptor Expression and Function in Aging. Journal of Immunology, 2002, 169, 4697-4701.	0.4	549
111	DNA Vaccine Expressing Conserved Influenza Virus Proteins Protective Against H5N1 Challenge Infection in Mice. Emerging Infectious Diseases, 2002, 8, 796-801.	2.0	153
112	Severe Impairment of Primary but Not Memory Responses to Influenza Viral Antigens in Aged Mice: Costimulation in Vivo Partially Reverses Impaired Primary Immune Responses. Cellular Immunology, 2001, 210, 1-4.	1.4	36
113	Heterosubtypic Immunity against Human Influenza A Viruses, Including Recently Emerged Avian H5 and H9 Viruses, Induced by FLUâ€"ISCOM Vaccine in Mice Requires both Cytotoxic T-Lymphocyte and Macrophage Function. Cellular Immunology, 2001, 211, 143-153.	1.4	121
114	Persistence of Memory CD8 T Cells in MHC Class I-Deficient Mice. Science, 1999, 286, 1377-1381.	6.0	659
115	Enhanced Antibody and Cytokine Responses to Influenza Viral Antigens in Perforin-Deficient Mice. Cellular Immunology, 1998, 187, 13-18.	1.4	33
116	Enhanced immune responses and resistance against infection in aged mice conferred by Flu-ISCOMs vaccine correlate with up-regulation of costimulatory molecule CD86. Vaccine, 1998, 16, 1698-1704.	1.7	19
117	Heterotypic Protection against Influenza by Immunostimulating Complexes Is Associated with the Induction of Crossâ€Reactive Cytotoxic T Lymphocytes. Journal of Infectious Diseases, 1998, 177, 1266-1274.	1.9	44
118	Protection against Respiratory Syncytial Virus Infection by DNA Immunization. Journal of Experimental Medicine, 1998, 188, 681-688.	4.2	114
119	Influenza (H1N1)â€"ISCOMs enhance immune responses and protection in aged mice. Mechanisms of Ageing and Development, 1997, 96, 157-169.	2.2	14
120	Dependence of mouse thymocyte-erythrocyte rosette formation on complete identity at class-I-MHC. Journal of Cellular Physiology, 1991, 148, 485-492.	2.0	2